One Wales Medicines interim decisions

Abiraterone for non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer (OW20)

Last review date: April 2024

Adalimumab for paediatric intermediate, posterior and pan-uveitis (OW04)

Last review date: November 2023

Arsenic trioxide for high risk acute promyelocytic leukaemia (OW06)

Last review date: September 2023

Azacitidine for progressive angioimmunoblastic T-cell lymphoma (OW16)

Last review date: February 2026

Bendamustine and rituximab for indolent lymphomas (OW08)

Last review date: March 2026

Bendamustine and rituximab for mantle cell lymphoma (OW09)

Last review date: March 2026

Bevacizumab for ovarian cancer (OW01)

Last review date: April 2025

Dabrafenib and trametinib for anaplastic thyroid cancer (OW27)

Last review date: October 2025

Denosumab (Prolia®) for osteoporosis in men (OW07)

Last review date: December 2022

Dostarlimab (Jemperli®) for locally advanced rectal cancer (OW26)

Last review date: October 2024

Infliximab for the treatment of ICI induced enterocolitis (OW21)

Last review date: March 2026

Infliximab for the treatment of ICI induced myocarditis (OW31)

Issue date: September 2025

Infliximab for the treatment of ICI induced pneumonitis (OW34)

Issue date: February 2026

Infliximab for the treatment of refractory pulmonary sarcoidosis (OW23)

Last review date: May 2024

Mepolizumab (Nucala®) for chronic eosinophilic pneumonia (OW15)

Last review date: August 2023

Nivolumab for oesophageal and gastric cancer (OW28)

Last review date: October 2025

Nivolumab plus ipilimumab for stage III melanoma (OW35)

Issue date: March 2026

Panitumumab (Vectibix®) rechallenge for metastatic colorectal cancer (OW29)

Issue date: June 2025

Rituximab for interstitial lung disease (OW13)

Last review date: June 2026

Rituximab for myasthenia gravis (OW12)

Last review date: December 2025